Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipidor and Cadila Pharmaceuticals have entered into a collaboration agreement on the commercialization of a sprayable anti-psoriatic product consisting of the generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO.
Subscribe to our email newsletter
The product targets patients with mild to moderate psoriasis. Under the collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.
Lipidor CEO Anders Carlsson said: "We are very pleased with our collaboration with Cadila Pharmaceuticals, which will enable us to bring this important psoriasis product to the market."
Cadila Pharmaceuticals chairman and managing director for India Rajiv Modi said: "Cadila Pharmaceuticals’ partnership with Lipidor AB evolves from its vision to partner with leading global research institutions to find novel, innovative and affordable solutions for unmet medical needs.
"Psoriasis is a condition with high prevalence in India and globally."
According to recent estimates psoriasis affects 2-3% of the world’s population. Psoriasis Vulgaris is a long lasting (chronic) autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors. Quality of life aspects, including self-consciousness and social withdrawal are important factors in the management of the disease including treatment compliance.
Various kinds of topical ointments, creams and lotions are commonly prescribed treatments for psoriasis, but they show low compliance rates, largely due to their greasiness and inability to absorb into the skin wherefore they are present on the skin for a long time after application.